Systemic lupus erythematosus patients eligible for chimeric antigen receptor T-cell therapy according to the 2024 EBMT and International Society for Cell and Gene Therapy expert-based recommendations: a 1-year clinical practice study in France

Retrospective analysis of CPs showed that very few severe SLE patients were enrolled in the CAR T-cell trial despite eligibility criteria. Streamlined referral pathways, multidisciplinary coordination and improved physician education are needed to enhance access to advanced cell and gene therapies.

Authors

Institutions

Publication Details

Journal
Cytotherapy
Published
2026-01-20
DOI
https://doi.org/10.1016/j.jcyt.2026.102057
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Systemic lupus erythematosus patients eligible for chimeric antigen receptor T-cell therapy according to the 2024 EBMT and International Society for Cell and Gene Therapy expert-based recommendations: a 1-year clinical practice study in France

Dominique Farge, Tamim Alsuliman, Zora Marjanovic, Catney Charles et al.
Cytotherapy
CAR-T cell therapy research
article

Systemic lupus erythematosus patients eligible for chimeric antigen receptor T-cell therapy according to the 2024 EBMT and International Society for Cell and Gene Therapy expert-based recommendations: a 1-year clinical practice study in France

Dominique Farge, Tamim Alsuliman, Zora Marjanovic, Catney Charles, Martin Nivet, Marie Jachiet, C. Beuvon, A. Maria, I. Munia, Mohamad Sabbah, Benjamin Crichi, Pedro Henrique Prata, Roberta Di Blasi, Robin Dhote, Sondess Hadj Khelifa, Catherine Thieblemont, Erwan Le Tallec, Louis Terriou
article en

Abstract

Retrospective analysis of CPs showed that very few severe SLE patients were enrolled in the CAR T-cell trial despite eligibility criteria. Streamlined referral pathways, multidisciplinary coordination and improved physician education are needed to enhance access to advanced cell and gene therapies.

CytotherapyVol. 28(5)
Université Paris Cité (FR), Centre Hospitalier Universitaire de Toulouse (FR), Sorbonne Université (FR), Université Sorbonne Paris Nord (FR), Centre Hospitalier de Saint-Quentin (FR), Institute for Regenerative Medicine & Biotherapy (FR), Assistance Publique – Hôpitaux de Paris (FR), Centre de Référence des Maladies Autoinflammatoires et des Amyloses (FR), Hôpital Saint-Antoine (FR), Institut de Recherche en Santé, Environnement et Travail (FR), Centre Hospitalier Universitaire de Poitiers (FR), Laboratoire National de Référence (MA), CHU Dijon Bourgogne (FR), Hôpital Rangueil (FR), Établissement Français du Sang (FR), Hôpital Avicenne (FR), Hôpital Universitaire Dupuytren (FR), Hôpital Saint-Louis (FR), Centre Hospitalier Universitaire de Rennes (FR), Institute of Infection and Immunity (CA)
Quality Education
Openalex Percentile: Top 83%
CAR-T cell therapy research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.